candesartan cilexetil has been researched along with Diabetic Retinopathy in 7 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
Diabetic Retinopathy: Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of the angiotensin II receptor blocker, candesartan cilexetil, on proteinuria was examined in a prospective, multicenter, randomized, double-blind study in Japanese subjects with type 2 diabetes." | 5.11 | Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy. ( Haneda, M; Kawamori, R; Kikkawa, R; Sakai, H, 2004) |
| " Candesartan cilexetil (TCV-116), a potent angiotensin II (AII) receptor antagonist, has beneficial effects on hypertension as well as on heart, renal and cerebrovascular disease." | 3.71 | The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats. ( Nagisa, Y; Nakagawa, S; Shintani, A, 2001) |
| "Candesartan cilexetil is an angiotensin II type 1 (AT[1]) receptor antagonist (angiotensin receptor blocker [ARB]) that inhibits the actions of angiotensin II on the renin-angiotensin-aldosterone system." | 2.47 | Differential clinical profile of candesartan compared to other angiotensin receptor blockers. ( Cernes, R; Mashavi, M; Zimlichman, R, 2011) |
| "It was launched in 1998 for the treatment of hypertension." | 2.45 | Candesartan: widening indications for this angiotensin II receptor blocker? ( Mendis, B; Page, SR, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mendis, B | 1 |
| Page, SR | 1 |
| Cernes, R | 1 |
| Mashavi, M | 1 |
| Zimlichman, R | 1 |
| Nagisa, Y | 2 |
| Shintani, A | 2 |
| Nakagawa, S | 2 |
| Haneda, M | 1 |
| Kikkawa, R | 1 |
| Sakai, H | 1 |
| Kawamori, R | 1 |
| Nakamura, H | 1 |
| Inoue, T | 1 |
| Arakawa, N | 1 |
| Shimizu, Y | 1 |
| Yoshigae, Y | 1 |
| Fujimori, I | 1 |
| Shimakawa, E | 1 |
| Toyoshi, T | 1 |
| Yokoyama, T | 1 |
| Sugiyama, T | 1 |
| Okuno, T | 1 |
| Fukuhara, M | 1 |
| Oku, H | 1 |
| Ikeda, T | 1 |
| Obayashi, H | 1 |
| Ohta, M | 1 |
| Fukui, M | 1 |
| Hasegawa, G | 1 |
| Nakamura, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Non-Randomized, Unblinded, Single-Center Trial of Oral Telmisartan Alone or Combined With Selected Standard of Care Therapies for Prostate Cancer[NCT06168487] | Early Phase 1 | 42 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for candesartan cilexetil and Diabetic Retinopathy
| Article | Year |
|---|---|
Candesartan: widening indications for this angiotensin II receptor blocker?
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases | 2009 |
Differential clinical profile of candesartan compared to other angiotensin receptor blockers.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Arteries; Benzimidazoles; Biphenyl Compounds; | 2011 |
[Ameliorative effects on retinal disorder in diabetic SHRSP (stroke-prone spontaneously hypertensive rat)].
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 2002 |
1 trial available for candesartan cilexetil and Diabetic Retinopathy
| Article | Year |
|---|---|
Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy.
Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Creatinine; Diabetes Mellitus, | 2004 |
3 other studies available for candesartan cilexetil and Diabetic Retinopathy
| Article | Year |
|---|---|
Pharmacological and pharmacokinetic study of olmesartan medoxomil in animal diabetic retinopathy models.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Area Under Curve; Benzimidazoles; Biphenyl Compoun | 2005 |
Angiotensin II receptor blocker inhibits abnormal accumulation of advanced glycation end products and retinal damage in a rat model of type 2 diabetes.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Animals; Arginine; Benzim | 2007 |
The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Blood | 2001 |